Company / R&D per Share
Ernexa Therapeutics Inc. R&D per Share History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$1.34
FY2025
5-year range
$0.01 / $2.03
FY2021-FY2025
Trend
+22.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D per Share has fluctuated over the past 6 years, ranging from $0.01 in FY2020 to $2.03 in FY2023.
Based on SEC 10-K filings.
1.34 in FY2025 with a 5-year CAGR of +172.4%.
Declined from $2.03 to $1.34 over the past 2 years.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +172.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, r&d per share increased 22.8% year-over-year.
- Peak r&d per share was recorded in FY2023.
- Lowest r&d per share in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score -8.07 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.34 | +22.8% |
| FY2024 | $1.09 | -46.0% |
| FY2023 | $2.03 | +22515.7% |
| FY2020 | $0.01 | -64.2% |
| FY2019 | $0.03 | -54.6% |
| FY2018 | $0.06 | - |
| FY2017 | - | - |
| FY2016 | - | - |
| FY2015 | - | - |
| FY2014 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026